Pharmaceutical Executive-01-01-2005
Pharmaceutical Executive
Citing cherry-picked patients, unrealistic dosing, and placebo control, payers will increasingly require that the proof for payment of drugs must come from head-to-head trials.
Pharmaceutical Executive
Heading the WHO list are pandemic influenza and antibiotic-resistant bacterial infections. Together the two could kill millions.
Advertisement
Advertisement
Trending on PharmExec
1
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
2
Report: Richard Pazdur Out as Director of CDER
3
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
4
Five Steps for Successful CGT Commercialization Through Health Systems Partnerships
5
